Cite Filings / FULC / 0001346824-25-000068
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G/A

Statement of Beneficial Ownership

Fulcrum Therapeutics, Inc. · Filed 2025-12-10 · Acc 0001346824-25-000068

Documents 1

  • SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

  • 2026-02-17 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-12-11 8-K Material agreement · Other events
  • 2025-12-11 424B5 Prospectus
  • 2025-12-10 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2025-12-10 4 10% owner sold 4,175,139 shares at an average $13.98 ($58,377,021)
  • 2025-12-10 FWP Free Writing Prospectus
  • 2025-11-13 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G · ADAR1 Capital Management, LLC 8.7%
  2. 2026-11-16 SCHEDULE 13G/A · EcoR1 Capital, LLC 8.9%
  3. 2026-11-13 SCHEDULE 13G/A · Nantahala Capital Management, LLC 8.62%
  4. 2026-11-13 SCHEDULE 13G/A · Montanova Capital, LLC 0%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…